Q2 2024 · 13F-HR
Logos Global Management LPholdings as filed
Filed 2024-08-14 · accession 0001172661-24-003502
$1.23B
Reported value
54
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78464A870 | XBI | SPDR SER TR | $185.4M | 15.1% | 2,000,000 | PUT | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $79.0M | 6.41% | 500,000 | CALL | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $76.7M | 6.23% | 2,000,000 | CALL | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $59.7M | 4.85% | 1,700,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $58.1M | 4.71% | 135,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $50.3M | 4.08% | 850,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $46.6M | 3.78% | 1,200,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $43.2M | 3.51% | 1,100,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $41.7M | 3.38% | 925,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $35.2M | 2.86% | 5,150,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $34.7M | 2.82% | 3,208,875 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $34.4M | 2.79% | 950,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $33.0M | 2.68% | 750,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $31.4M | 2.55% | 750,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $28.4M | 2.31% | 1,500,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $28.0M | 2.28% | 1,476,061 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $23.7M | 1.92% | 150,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $18.8M | 1.52% | 800,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $17.7M | 1.43% | 450,000 | CALL | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $16.9M | 1.37% | 5,032,501 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $16.2M | 1.31% | 3,300,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $15.3M | 1.25% | 400,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $15.2M | 1.23% | 575,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $14.8M | 1.20% | 195,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $14.6M | 1.19% | 375,000 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $14.3M | 1.16% | 300,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $14.2M | 1.15% | 1,050,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $13.9M | 1.13% | 5,900,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $13.9M | 1.13% | 595,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $13.5M | 1.10% | 575,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $11.3M | 0.92% | 1,200,000 | Common | SOLE |
| 23256X100 | — | CYBIN INC | $10.8M | 0.88% | 40,000,000 | Common | SOLE |
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $10.4M | 0.85% | 1,301,518 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $10.4M | 0.84% | 3,850,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $9.4M | 0.76% | 265,000 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $9.3M | 0.76% | 1,500,000 | CALL | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $8.7M | 0.70% | 250,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $8.5M | 0.69% | 1,300,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $8.3M | 0.68% | 2,800,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $7.5M | 0.61% | 350,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $7.3M | 0.60% | 1,500,000 | CALL | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $7.0M | 0.57% | 1,159,030 | Common | SOLE |
| 53566P109 | LCTX | LINEAGE CELL THERAPEUTICS IN | $4.7M | 0.38% | 4,700,000 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $4.7M | 0.38% | 3,000,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $4.5M | 0.37% | 500,000 | Common | SOLE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $4.0M | 0.32% | 2,500,000 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $2.9M | 0.24% | 300,000 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $2.9M | 0.24% | 2,900,000 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $2.9M | 0.23% | 416,666 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $2.7M | 0.22% | 600,000 | Common | SOLE |
| 816212302 | RNAC | CARTESIAN THERAPEUTICS INC | $2.4M | 0.20% | 90,000 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $1.7M | 0.14% | 3,469,927 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $577,778 | 0.05% | 493,827 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $10,667 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.